Crown Bioscience International
| Company type | Public |
|---|---|
| Industry | Contract research organizations Pharmaceutical Biotechnology |
| Headquarters | San Diego, California, United States |
| Products | Oncology platforms and patient derived xenograft services for drug research |
| Website | www.crownbio.com/ |
Crown Bioscience International, also known as CrownBio, is a contract research organization focused on patient derived xenografts used in drug screening. The company was acquired by JSR Corporation in January 2018.[1]
Company profile
CrownBio was founded in 2006 as a drug-testing platform centered around xenografts.[2] The company keeps a library of cancer models used for drug-testing that precedes clinical trials.[3] The company applied for listing on the Taipei Exchange in 2016 as part of its integration into Asian markets, and continued to expand its operations from higher revenues.[3]
In 2018, CrownBio merged with JSR Corporation as part of JSR Corporation's expansion into the therapeutic market.[1]
Products
CrownBio's signature products include a library of xenograft models used for drug testing and contract research services for experimental drug screening. The company has at least 8,000 viable human tumors that can be used for the evaluation of drugs used in oncology studies.[4]
References
- ^ a b Fassbender, Melissa (4 January 2018). "JSR: CrownBio purchase to support 'major opportunity' in preclinical space". Outsourcing-Pharma. Retrieved 29 January 2018.
- ^ "Crown Bioscience International". Reuters. 19 December 2017. Archived from the original on January 30, 2018. Retrieved 29 January 2018.
- ^ a b Daverman, Richard; Ye, Henry (29 July 2016). "CrownBio is One of Several Life Science Companies Planning Taiwan IPO". China Bio Today. Retrieved 29 January 2018.
- ^ Liu, Angus (4 January 2017). "CrownBio in $1M new-facility collab with New Iberia Research Center". Fierce Biotech. Retrieved 29 January 2018.